Tramutola Antonella, Triplett Judy C, Di Domenico Fabio, Niedowicz Dana M, Murphy Michael P, Coccia Raffaella, Perluigi Marzia, Butterfield D Allan
Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy.
J Neurochem. 2015 Jun;133(5):739-49. doi: 10.1111/jnc.13037. Epub 2015 Feb 26.
The clinical symptoms of Alzheimer disease (AD) include a gradual memory loss and subsequent dementia, and neuropathological deposition of senile plaques and neurofibrillary tangles. At the molecular level, AD subjects present overt amyloid β (Aβ) production and tau hyperphosphorylation. Aβ species have been proposed to overactivate the phosphoinositide3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) axis, which plays a central role in proteostasis. The current study investigated the status of the PI3K/Akt/mTOR pathway in post-mortem tissue from the inferior parietal lobule (IPL) at three different stages of AD: late AD, amnestic mild cognitive impairment (MCI) and pre-clinical AD (PCAD). Our findings suggest that the alteration of mTOR signaling and autophagy occurs at early stages of AD. We found a significant increase in Aβ (1-42) levels, associated with reduction in autophagy (Beclin-1 and LC-3) observed in PCAD, MCI, and AD subjects. Related to the autophagy impairment, we found a hyperactivation of PI3K/Akt/mTOR pathway in IPL of MCI and AD subjects, but not in PCAD, along with a significant decrease in phosphatase and tensin homolog. An increase in two mTOR downstream targets, p70S6K and 4EBP1, occurred in AD and MCI subjects. Both AD and MCI subjects showed increased, insulin receptor substrate 1, a candidate biomarker of brain insulin resistance, and GSK-3β, a kinase targeting tau phosphorylation. Nevertheless, tau phosphorylation was increased in the clinical groups. The results hint at a link between Aβ and the PI3K/Akt/mTOR axis and provide further insights into the relationship between AD pathology and insulin resistance. In addition, we speculate that the alteration of mTOR signaling in the IPL of AD and MCI subjects, but not in PCAD, is due to the lack of substantial increase in oxidative stress. The figure represents the three different stages of Alzheimer Disease: Preclinical Alzheimer Disease (PCAD), Mild cognitive impairment (MCI) and late stage of Alzheimer Disease. The progression of the disease is associated with a reduction in autophagy (Beclin-1 and LC-3) observed in Inferior parietal lobe of PCAD, MCI, and AD subjects (light red). Related to the autophagy impairment, the graph shows the impairment of PI3K/Akt/mTOR in MCI and AD subjects (dark red).
阿尔茨海默病(AD)的临床症状包括逐渐的记忆丧失及随后的痴呆,以及老年斑和神经原纤维缠结的神经病理学沉积。在分子水平上,AD患者存在明显的淀粉样β蛋白(Aβ)生成及tau蛋白过度磷酸化。有人提出Aβ会过度激活磷酸肌醇-3-激酶(PI3K)/蛋白激酶B(Akt)/雷帕霉素哺乳动物靶蛋白(mTOR)轴,该轴在蛋白质稳态中起核心作用。本研究调查了AD三个不同阶段(晚期AD、遗忘型轻度认知障碍[MCI]和临床前期AD[PCAD])下顶叶小叶(IPL)尸检组织中PI3K/Akt/mTOR通路的状态。我们的研究结果表明,mTOR信号传导和自噬的改变发生在AD的早期阶段。我们发现,在PCAD、MCI和AD患者中,Aβ(1-42)水平显著升高,同时自噬(Beclin-1和LC-3)减少。与自噬受损相关,我们发现MCI和AD患者的IPL中PI3K/Akt/mTOR通路过度激活,但PCAD患者未出现,同时磷酸酶和张力蛋白同源物显著减少。AD和MCI患者中,mTOR的两个下游靶点p70核糖体蛋白S6激酶(p70S6K)和真核翻译起始因子4E结合蛋白1(4EBP1)增加。AD和MCI患者均显示脑胰岛素抵抗的候选生物标志物胰岛素受体底物1以及靶向tau蛋白磷酸化的激酶糖原合成酶激酶-3β(GSK-3β)增加。然而,临床组中tau蛋白磷酸化增加。这些结果提示了Aβ与PI3K/Akt/mTOR轴之间的联系,并为AD病理学与胰岛素抵抗之间的关系提供了进一步的见解。此外,我们推测AD和MCI患者IPL中mTOR信号传导的改变(PCAD患者未出现)是由于氧化应激没有大幅增加所致。图中展示了阿尔茨海默病的三个不同阶段:临床前期阿尔茨海默病(PCAD)、轻度认知障碍(MCI)和阿尔茨海默病晚期。疾病进展与PCAD、MCI和AD患者下顶叶小叶中观察到的自噬(Beclin-1和LC-3)减少有关(浅红色)。与自噬受损相关,该图显示了MCI和AD患者中PI3K/Akt/mTOR的受损情况(深红色)。